PT659439E - Imunoconjugados - Google Patents

Imunoconjugados

Info

Publication number
PT659439E
PT659439E PT94119712T PT94119712T PT659439E PT 659439 E PT659439 E PT 659439E PT 94119712 T PT94119712 T PT 94119712T PT 94119712 T PT94119712 T PT 94119712T PT 659439 E PT659439 E PT 659439E
Authority
PT
Portugal
Prior art keywords
biologically active
tumor
active ligand
new
preferentially
Prior art date
Application number
PT94119712T
Other languages
English (en)
Inventor
Wolfgang Strittmatter
Carlota-Silvia Jaeggle
Ilka Von Hoegen
Uwe Hofmann
Joerg Stadlmueller
Siegfried Matzku
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of PT659439E publication Critical patent/PT659439E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5406—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5418—IL-7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/028—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a herpesvirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PT94119712T 1993-12-24 1994-12-14 Imunoconjugados PT659439E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP93120865 1993-12-24

Publications (1)

Publication Number Publication Date
PT659439E true PT659439E (pt) 2002-04-29

Family

ID=8213530

Family Applications (1)

Application Number Title Priority Date Filing Date
PT94119712T PT659439E (pt) 1993-12-24 1994-12-14 Imunoconjugados

Country Status (19)

Country Link
US (1) US6979726B1 (pt)
EP (1) EP0659439B1 (pt)
JP (2) JPH07223968A (pt)
KR (1) KR950016781A (pt)
AT (1) ATE207366T1 (pt)
AU (1) AU688817B2 (pt)
CA (1) CA2138928C (pt)
CZ (1) CZ289099B6 (pt)
DE (1) DE69428764T2 (pt)
DK (1) DK0659439T3 (pt)
ES (1) ES2166368T3 (pt)
HU (1) HU219680B (pt)
NO (1) NO315903B1 (pt)
PL (1) PL178793B1 (pt)
PT (1) PT659439E (pt)
RU (1) RU2129018C1 (pt)
SK (1) SK283494B6 (pt)
UA (1) UA41888C2 (pt)
ZA (1) ZA9410282B (pt)

Families Citing this family (173)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) * 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
WO1998011241A1 (en) * 1996-09-16 1998-03-19 Merck Patent Gmbh Oligocistronic expression system for the production of heteromeric proteins
EP2112167A3 (en) 1999-06-25 2010-12-22 Genentech, Inc. Humanized ANTI-ERBB2 antibodies and treatment with ANTI-ERBB2 antibodies
MXPA05000403A (es) 2002-07-15 2005-07-22 Genentech Inc Metodos para identificar tumores que responden al tratamiento con anticuerpos contra erbb2.
KR101438983B1 (ko) 2003-11-06 2014-09-05 시애틀 지네틱스, 인크. 리간드에 접합될 수 있는 모노메틸발린 화합물
RU2369616C2 (ru) 2003-12-30 2009-10-10 Мерк Патент Гмбх Слитые белки il-7
WO2005070020A2 (en) 2004-01-23 2005-08-04 The Regents Of The University Of Colorado Gefitinib sensitivity-related gene expression and products and methods related thereto
EP1737489B1 (en) 2004-04-08 2012-01-11 David B Agus ErbB2 antagonists for tumor pain therapy
AU2005249492B2 (en) 2004-05-27 2011-09-22 The Regents Of The University Of Colorado Methods for prediction of clinical outcome to epidermal growth factor receptor inhibitors by cancer patients
AU2005249490B2 (en) 2004-06-01 2010-07-29 Genentech, Inc. Antibody drug conjugates and methods
PL1791565T3 (pl) 2004-09-23 2016-10-31 Modyfikowane cysteiną przeciwciała i koniugaty
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
CN101141981A (zh) 2005-01-21 2008-03-12 健泰科生物技术公司 Her抗体的固定剂量给药
EP2399605A1 (en) 2005-02-23 2011-12-28 Genentech, Inc. Extending time to disease progression or survival in cancer patients
AR053272A1 (es) 2005-05-11 2007-04-25 Hoffmann La Roche Determinacion de responsivos a la quimioterapia
KR101397290B1 (ko) 2005-12-30 2014-05-21 메르크 파텐트 게엠베하 감소한 면역원성을 가지는 항-ｃｄ19 항체
JP5175214B2 (ja) 2005-12-30 2013-04-03 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 改良された安定性を有するインターロイキン−１２ｐ４０変種
EP2030984B1 (en) * 2006-06-16 2011-05-11 Onco Therapy Science, Inc. Sparc-derived cancer rejection antigen peptide and pharmaceutical comprising the same
US20100008910A1 (en) 2006-09-12 2010-01-14 John Chant Methods and compositions for the diagnosis and treatment of cancer
WO2008109440A2 (en) 2007-03-02 2008-09-12 Genentech, Inc. Predicting response to a her dimerisation inhibitor based on low her3 expression
CA3006428A1 (en) 2007-06-08 2008-12-18 Genentech, Inc. Gene expression markers of tumor resistance to her2 inhibitor treatment
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
KR20130080871A (ko) 2009-03-20 2013-07-15 제넨테크, 인크. 이중특이적 항-ｈｅｒ 항체
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
SG178443A1 (en) * 2009-08-17 2012-04-27 Roche Glycart Ag Targeted immunoconjugates
CA2781682A1 (en) 2009-12-04 2011-06-09 Genentech, Inc. Multispecific antibodies, antibody analogs, compositions, and methods
TW201129565A (en) 2010-01-12 2011-09-01 Hoffmann La Roche Tricyclic heterocyclic compounds, compositions and methods of use thereof
SI2536748T1 (sl) 2010-02-18 2014-12-31 Genentech, Inc. Nevrogulinski antagonisti in njihova uporaba pri zdravljenju raka
WO2011112935A2 (en) * 2010-03-12 2011-09-15 The Regents Of The University Of California Antibody fusion proteins with disrupted heparin-binding activity
CA2793024A1 (en) 2010-03-17 2011-09-22 F. Hoffmann-La Roche Ag Imidazopyridine compounds, compositions and methods of use
CA2793892A1 (en) 2010-04-16 2011-10-20 Elizabeth Punnoose Foxo3a as predictive biomarker for pi3k/akt kinase pathway inhibitor efficacy
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
US20120089541A1 (en) 2010-08-31 2012-04-12 Genentech, Inc. Biomarkers and methods of treatment
AR082974A1 (es) 2010-09-15 2013-01-23 Hoffmann La Roche Derivados de azabenzotiazol, composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos para tratar enfermedades inflamatorias
AR083495A1 (es) 2010-10-22 2013-02-27 Esbatech Alcon Biomed Res Unit Anticuerpos estables y solubles
BR112013010569A2 (pt) 2010-10-29 2017-07-04 Immunogen Inc moléculas de ligação de egfr não antagonísticas e imunoconjugados das mesma
EA201390472A1 (ru) 2010-10-29 2014-02-28 Иммьюноджен, Инк. Новые молекулы, связывающиеся с egfr, и их иммуноконъюгаты
US9309322B2 (en) 2010-11-12 2016-04-12 Scott & White Healthcare (Swh) Antibodies to tumor endothelial marker 8
BR112013011520A2 (pt) 2010-11-19 2019-09-24 Hoffmann La Roche pirazolo piridinas e pirazolo piridinas e seu uso como inibidores de tyk2
WO2012085176A1 (en) 2010-12-23 2012-06-28 F. Hoffmann-La Roche Ag Tricyclic pyrazinone compounds, compositions and methods of use thereof as janus kinase inhibitors
WO2013007768A1 (en) 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors
WO2013007765A1 (en) 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Fused tricyclic compounds for use as inhibitors of janus kinases
BR112014003237A2 (pt) 2011-08-12 2017-04-25 Hoffmann La Roche compostos de indazol, composições e métodos de uso
BR112014003431A2 (pt) 2011-08-17 2017-06-13 Genentech Inc anticorpo, ácido nucleico, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, agente farmacêutico, uso do anticorpo, método de tratamento de um indivíduo que tem câncer e método de aumento de tempo para recorrência de tumor
WO2013041539A1 (en) 2011-09-20 2013-03-28 F. Hoffmann-La Roche Ag Imidazopyridine compounds, compositions and methods of use
AU2012340686A1 (en) 2011-11-21 2014-06-19 Immunogen, Inc. Method of treatment of tumors that are resistant to EGFR therapies by EGFR antibody cytotoxic agent conjugate
AU2012346540C1 (en) 2011-11-30 2019-07-04 Genentech, Inc. ErbB3 mutations in cancer
BR112014024017A8 (pt) 2012-03-27 2017-07-25 Genentech Inc Métodos de tratamento de um tipo de câncer, de tratamento do carcinoma, para selecionar uma terapia e para quantificação e inibidor de her3
CN104994879A (zh) 2013-02-22 2015-10-21 霍夫曼-拉罗奇有限公司 治疗癌症和预防药物抗性的方法
BR112015021423A2 (pt) 2013-03-06 2017-07-18 Genentech Inc métodos de tratamento de câncer, de células de câncer e de câncer resistente a antagonista de egfr, métodos de aumento da sensibilidade e da eficácia de tratamento de câncer e métodos de atraso, de tratamento de indivíduos com câncer e de extensão
BR112015022545A2 (pt) 2013-03-13 2017-07-18 Constellation Pharmaceuticals Inc compostos de pirazolo e os usos disso
RU2015139054A (ru) 2013-03-14 2017-04-19 Дженентек, Инк. Способы лечения рака и профилактики лекарственной резистентности рака
AU2014239903A1 (en) 2013-03-14 2015-09-17 Genentech, Inc. Combinations of a MEK inhibitor compound with an HER3/EGFR inhibitor compound and methods of use
KR20150130451A (ko) 2013-03-15 2015-11-23 제넨테크, 인크. 암 치료 방법 및 항암제 내성 예방을 위한 방법
TW201945032A (zh) * 2013-03-15 2019-12-01 德商艾伯維德國有限及兩合公司 抗-egfr抗體藥物結合物調配物
CN104250302B (zh) * 2013-06-26 2017-11-14 上海君实生物医药科技股份有限公司 抗pd‑1抗体及其应用
EP3041474B1 (en) 2013-09-05 2020-03-18 Genentech, Inc. Antiproliferative compounds
TW201605857A (zh) 2013-10-03 2016-02-16 赫孚孟拉羅股份公司 Ｃｄｋ８之醫療性抑制劑及其用途
US20150147333A1 (en) 2013-10-18 2015-05-28 Genentech, Inc. Anti-rspo antibodies and methods of use
KR20160099092A (ko) 2013-12-17 2016-08-19 제넨테크, 인크. Ox40 결합 효능제 및 pd-1 축 결합 길항제를 포함하는 조합 요법
KR20240017102A (ko) 2013-12-17 2024-02-06 제넨테크, 인크. Pd-1 축 결합 길항제 및 탁산을 이용한 암 치료 방법
JP2017516458A (ja) 2014-03-24 2017-06-22 ジェネンテック， インコーポレイテッド ｃ−ｍｅｔ拮抗剤による癌治療及びｃ−ｍｅｔ拮抗剤のＨＧＦ発現との相関
MX2016012779A (es) 2014-03-31 2017-04-27 Genentech Inc Terapia de combinacion con agentes antiangiogénesis y agonistas de unión a ox40.
PT3126394T (pt) 2014-03-31 2019-12-19 Hoffmann La Roche Anticorpos anti-ox40 e métodos de utilização
CA2944528C (en) * 2014-04-03 2021-08-10 Cellectis Cd33 specific chimeric antigen receptors for cancer immunotherapy
CN107074823B (zh) 2014-09-05 2021-05-04 基因泰克公司 治疗性化合物及其用途
WO2016044694A1 (en) 2014-09-19 2016-03-24 Genentech, Inc. Use of cbp/ep300 and bet inhibitors for treatment of cancer
EP3204379B1 (en) 2014-10-10 2019-03-06 Genentech, Inc. Pyrrolidine amide compounds as histone demethylase inhibitors
EP3215850B1 (en) 2014-11-03 2019-07-03 F. Hoffmann-La Roche AG Assays for detecting t cell immune subsets and methods of use thereof
US20160160290A1 (en) 2014-11-03 2016-06-09 Genentech, Inc. Methods and biomarkers for predicting efficacy and evaluation of an ox40 agonist treatment
US20160152720A1 (en) 2014-11-06 2016-06-02 Genentech, Inc. Combination therapy comprising ox40 binding agonists and tigit inhibitors
MA40943A (fr) 2014-11-10 2017-09-19 Constellation Pharmaceuticals Inc Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
MA40940A (fr) 2014-11-10 2017-09-19 Constellation Pharmaceuticals Inc Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
CN107108613B (zh) 2014-11-10 2020-02-25 基因泰克公司 布罗莫结构域抑制剂及其用途
AU2015350242A1 (en) 2014-11-17 2017-06-29 Genentech, Inc. Combination therapy comprising OX40 binding agonists and PD-1 axis binding antagonists
JP6771464B2 (ja) 2014-11-27 2020-10-21 ジェネンテック， インコーポレイテッド Ｃｂｐおよび／またはｅｐ３００インヒビターとしての、４，５，６，７−テトラヒドロ−１ｈ−ピラゾロ［４，３−ｃ］ピリジン−３−アミン化合物
EP3229836B1 (en) 2014-12-09 2019-11-13 Institut National de la Sante et de la Recherche Medicale (INSERM) Human monoclonal antibodies against axl
MX2017006864A (es) 2014-12-23 2017-08-28 Genentech Inc Composiciones y métodos para tratar y diagnosticar cánceres resistentes a la quimioterapia.
EP3240908A2 (en) 2014-12-30 2017-11-08 F. Hoffmann-La Roche AG Methods and compositions for prognosis and treatment of cancers
JP6855379B2 (ja) 2015-01-09 2021-04-07 ジェネンテック， インコーポレイテッド 癌の処置のためのヒストンデメチラーゼｋｄｍ２ｂのインヒビターとしての（ピペリジン−３−イル）（ナフタレン−２−イル）メタノン誘導体および関連化合物
JP6659703B2 (ja) 2015-01-09 2020-03-04 ジェネンテック， インコーポレイテッド ピリダジノン誘導体および癌の処置におけるそれらの使用
JP6889661B2 (ja) 2015-01-09 2021-06-18 ジェネンテック， インコーポレイテッド ４，５−ジヒドロイミダゾール誘導体およびヒストンジメチラーゼ（ｋｄｍ２ｂ）インヒビターとしてのその使用
US20180318414A1 (en) 2015-01-12 2018-11-08 Children's Medical Center Corporation Pro-Inflammatory and Adjuvant Functions of Toll-Like Receptor 4 Antagonists
JP6709792B2 (ja) 2015-01-29 2020-06-17 ジェネンテック， インコーポレイテッド 治療用化合物およびその使用
CN107438593B (zh) 2015-01-30 2020-10-30 基因泰克公司 治疗化合物及其用途
CN107249641B (zh) * 2015-02-18 2021-07-09 豪夫迈·罗氏有限公司 用于特异性诱导针对靶细胞的t细胞细胞毒性的免疫缀合物
MA41598A (fr) 2015-02-25 2018-01-02 Constellation Pharmaceuticals Inc Composés thérapeutiques de pyridazine et leurs utilisations
WO2016135041A1 (en) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and antibodies comprising thereof for promoting apoptosis
WO2016164480A1 (en) 2015-04-07 2016-10-13 Genentech, Inc. Antigen binding complex having agonistic activity and methods of use
IL255312B (en) 2015-05-12 2022-08-01 Genentech Inc Therapeutic and diagnostic methods for cancer containing a pd–l1 binding antagonist
EP3708681A1 (en) 2015-05-29 2020-09-16 F. Hoffmann-La Roche AG Therapeutic and diagnostic methods for cancer
CN107810011A (zh) 2015-06-08 2018-03-16 豪夫迈·罗氏有限公司 使用抗ox40抗体治疗癌症的方法
EP3303397A1 (en) 2015-06-08 2018-04-11 H. Hoffnabb-La Roche Ag Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists
CA2986263A1 (en) 2015-06-17 2016-12-22 Genentech, Inc. Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes
DK3341376T3 (da) 2015-08-26 2021-03-29 Fundacion Del Sector Publico Estatal Centro Nac De Investigaciones Oncologicas Carlos Iii F S P Cnio Kondenserede tricykliske forbindelser som proteinkinase-inhibitorer
RU2732591C2 (ru) 2015-09-25 2020-09-21 Дженентек, Инк. Анти-tigit антитела и способы применения
WO2017106647A1 (en) 2015-12-16 2017-06-22 Genentech, Inc. Process for the preparation of tricyclic pi3k inhibitor compounds and methods for using the same for the treatment of cancer
CN108368179B (zh) 2016-01-08 2022-08-23 豪夫迈·罗氏有限公司 使用pd-1轴结合拮抗剂和抗cea/抗cd3双特异性抗体治疗cea阳性癌症的方法
AU2017225854B2 (en) 2016-02-29 2020-11-19 Foundation Medicine, Inc. Therapeutic and diagnostic methods for cancer
WO2017180864A1 (en) 2016-04-14 2017-10-19 Genentech, Inc. Anti-rspo3 antibodies and methods of use
CA3019921A1 (en) 2016-04-15 2017-10-19 Genentech, Inc. Methods for monitoring and treating cancer
WO2017180581A1 (en) 2016-04-15 2017-10-19 Genentech, Inc. Diagnostic and therapeutic methods for cancer
CN109154027A (zh) 2016-04-15 2019-01-04 豪夫迈·罗氏有限公司 用于监测和治疗癌症的方法
US20190151346A1 (en) 2016-05-10 2019-05-23 INSERM (Institute National de la Santé et de la Recherche Médicale) Combinations therapies for the treatment of cancer
WO2017205536A2 (en) 2016-05-24 2017-11-30 Genentech, Inc. Therapeutic compounds and uses thereof
WO2017205538A1 (en) 2016-05-24 2017-11-30 Genentech, Inc. Pyrazolopyridine derivatives for the treatment of cancer
CN109312407A (zh) 2016-06-08 2019-02-05 豪夫迈·罗氏有限公司 用于癌症的诊断和治疗方法
EP3494139B1 (en) 2016-08-05 2022-01-12 F. Hoffmann-La Roche AG Multivalent and multiepitopic anitibodies having agonistic activity and methods of use
CN109476748B (zh) 2016-08-08 2023-05-23 豪夫迈·罗氏有限公司 用于癌症的治疗和诊断方法
KR20190072528A (ko) 2016-10-06 2019-06-25 제넨테크, 인크. 암에 대한 치료 및 진단 방법
EP3532091A2 (en) 2016-10-29 2019-09-04 H. Hoffnabb-La Roche Ag Anti-mic antibidies and methods of use
TW201837467A (zh) 2017-03-01 2018-10-16 美商建南德克公司 用於癌症之診斷及治療方法
SG11201908929VA (en) * 2017-03-31 2019-10-30 Univ Leland Stanford Junior Synthekine compositions and methods of use
BR112019021411A2 (pt) 2017-04-13 2020-05-05 Hoffmann La Roche métodos para tratar ou retardar a progressão do câncer e para melhorar a função, usos de um imunoconjugado, de um agonista, de um antagonista, composições, kit e invenção
AU2018316343A1 (en) 2017-08-11 2020-02-13 Genentech, Inc. Anti-CD8 antibodies and uses thereof
AU2018329925A1 (en) 2017-09-08 2020-03-05 F. Hoffmann-La Roche Ag Diagnostic and therapeutic methods for cancer
EP3710001A4 (en) 2017-10-27 2021-07-14 University Of Virginia Patent Foundation COMPOUNDS AND PROCEDURES FOR REGULATING, LIMITING OR INHIBITING AVIL EXPRESSION
EP3707510B1 (en) 2017-11-06 2024-06-26 F. Hoffmann-La Roche AG Diagnostic and therapeutic methods for cancer
CA3092108A1 (en) 2018-02-26 2019-08-29 Genentech, Inc. Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
WO2019226514A2 (en) 2018-05-21 2019-11-28 Nanostring Technologies, Inc. Molecular gene signatures and methods of using same
CA3103017A1 (en) 2018-06-23 2019-12-26 Genentech, Inc. Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor
MX2021000558A (es) 2018-07-18 2021-04-13 Genentech Inc Metodos para tratar el cancer de pulmon con un antagonista de fijacion al eje pd-1, un antimetabolito y un agente de platino.
WO2020051099A1 (en) 2018-09-03 2020-03-12 Genentech, Inc. Carboxamide and sulfonamide derivatives useful as tead modulators
WO2020061060A1 (en) 2018-09-19 2020-03-26 Genentech, Inc. Therapeutic and diagnostic methods for bladder cancer
CA3111809A1 (en) 2018-09-21 2020-03-26 Genentech, Inc. Diagnostic methods for triple-negative breast cancer
CA3116324A1 (en) 2018-10-18 2020-04-23 Genentech, Inc. Diagnostic and therapeutic methods for sarcomatoid kidney cancer
CN112166122A (zh) * 2018-12-13 2021-01-01 丁邦 抗体-肿瘤坏死因子α融合蛋白及其制法和应用
WO2020163589A1 (en) 2019-02-08 2020-08-13 Genentech, Inc. Diagnostic and therapeutic methods for cancer
CN113677994A (zh) 2019-02-27 2021-11-19 外延轴治疗股份有限公司 用于评估t细胞功能和预测对疗法的应答的方法和药剂
JP2022521773A (ja) 2019-02-27 2022-04-12 ジェネンテック， インコーポレイテッド 抗ｔｉｇｉｔ抗体と抗ｃｄ２０抗体又は抗ｃｄ３８抗体とによる処置のための投薬
WO2020223233A1 (en) 2019-04-30 2020-11-05 Genentech, Inc. Prognostic and therapeutic methods for colorectal cancer
WO2020226986A2 (en) 2019-05-03 2020-11-12 Genentech, Inc. Methods of treating cancer with an anti-pd-l1 antibody
CN112300279A (zh) 2019-07-26 2021-02-02 上海复宏汉霖生物技术股份有限公司 针对抗cd73抗体和变体的方法和组合物
MX2022002738A (es) 2019-09-04 2022-06-27 Genentech Inc Agentes de union a cd8 y uso de los mismos.
AU2020351734A1 (en) 2019-09-27 2022-04-14 Genentech, Inc. Dosing for treatment with anti-TIGIT and anti-PD-L1 antagonist antibodies
WO2021083949A1 (en) 2019-10-29 2021-05-06 F. Hoffmann-La Roche Ag Bifunctional compounds for the treatment of cancer
KR20220092580A (ko) 2019-11-06 2022-07-01 제넨테크, 인크. 혈액암의 치료를 위한 진단과 치료 방법
KR20220101138A (ko) 2019-11-13 2022-07-19 제넨테크, 인크. 치료적 화합물 및 사용 방법
AU2020403145A1 (en) 2019-12-13 2022-07-07 Genentech, Inc. Anti-Ly6G6D antibodies and methods of use
WO2021127404A1 (en) 2019-12-20 2021-06-24 Erasca, Inc. Tricyclic pyridones and pyrimidones
WO2021194481A1 (en) 2020-03-24 2021-09-30 Genentech, Inc. Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
WO2021177980A1 (en) 2020-03-06 2021-09-10 Genentech, Inc. Combination therapy for cancer comprising pd-1 axis binding antagonist and il6 antagonist
CN115698717A (zh) 2020-04-03 2023-02-03 基因泰克公司 癌症的治疗和诊断方法
WO2021222167A1 (en) 2020-04-28 2021-11-04 Genentech, Inc. Methods and compositions for non-small cell lung cancer immunotherapy
EP3915576A1 (en) 2020-05-28 2021-12-01 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Chimeric antigen receptors specific for p95her2 and uses thereof
AU2021293038A1 (en) 2020-06-16 2023-02-02 F. Hoffmann-La Roche Ag Methods and compositions for treating triple-negative breast cancer
IL298946A (en) 2020-06-18 2023-02-01 Genentech Inc Treatment with anti-TIGIT antibodies and PD-1 spindle-binding antagonists
US20230235408A1 (en) 2020-06-30 2023-07-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the risk of recurrence and/or death of patients suffering from a solid cancer after preoperative adjuvant therapies
US20230266322A1 (en) 2020-06-30 2023-08-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the risk of recurrence and/or death of patients suffering from a solid cancer after preoperative adjuvant therapy and radical surgery
EP3939999A1 (en) 2020-07-14 2022-01-19 Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) Interleukin 11 receptor alpha subunit (il11ra) neutralizing antibodies and uses thereof
US11787775B2 (en) 2020-07-24 2023-10-17 Genentech, Inc. Therapeutic compounds and methods of use
CN116568824A (zh) 2020-08-03 2023-08-08 基因泰克公司 淋巴瘤的诊断和治疗方法
WO2022036146A1 (en) 2020-08-12 2022-02-17 Genentech, Inc. Diagnostic and therapeutic methods for cancer
CA3193952A1 (en) 2020-10-05 2022-04-14 Bernard Martin Fine Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
US20230107642A1 (en) 2020-12-18 2023-04-06 Erasca, Inc. Tricyclic pyridones and pyrimidones
JP2024506339A (ja) 2021-02-12 2024-02-13 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト がんの治療のための二環式テトラヒドロアゼピン誘導体
KR20240026948A (ko) 2021-05-25 2024-02-29 에라스카, 아이엔씨. 황 함유 헤테로방향족 트리사이클릭 kras 억제제
WO2022266206A1 (en) 2021-06-16 2022-12-22 Erasca, Inc. Kras inhibitor conjugates
TW202321261A (zh) 2021-08-10 2023-06-01 美商伊瑞斯卡公司 選擇性ｋｒａｓ抑制劑
US20230203062A1 (en) 2021-11-24 2023-06-29 Genentech, Inc. Therapeutic compounds and methods of use
TW202332429A (zh) 2021-11-24 2023-08-16 美商建南德克公司 治療性化合物及其使用方法
EP4253418A1 (en) 2022-03-29 2023-10-04 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Immune cells expressing chimeric antigen receptors and bispecific antibodies and uses thereof
WO2023191816A1 (en) 2022-04-01 2023-10-05 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
WO2023219613A1 (en) 2022-05-11 2023-11-16 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
WO2023240058A2 (en) 2022-06-07 2023-12-14 Genentech, Inc. Prognostic and therapeutic methods for cancer
WO2024015897A1 (en) 2022-07-13 2024-01-18 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
WO2024020432A1 (en) 2022-07-19 2024-01-25 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
WO2024033458A1 (en) 2022-08-11 2024-02-15 F. Hoffmann-La Roche Ag Bicyclic tetrahydroazepine derivatives
WO2024033388A1 (en) 2022-08-11 2024-02-15 F. Hoffmann-La Roche Ag Bicyclic tetrahydrothiazepine derivatives
WO2024033389A1 (en) 2022-08-11 2024-02-15 F. Hoffmann-La Roche Ag Bicyclic tetrahydrothiazepine derivatives
WO2024033457A1 (en) 2022-08-11 2024-02-15 F. Hoffmann-La Roche Ag Bicyclic tetrahydrothiazepine derivatives
WO2024085242A2 (en) 2022-10-21 2024-04-25 Kawasaki Institute Of Industrial Promotion Non-fouling or super stealth vesicle
WO2024091991A1 (en) 2022-10-25 2024-05-02 Genentech, Inc. Therapeutic and diagnostic methods for multiple myeloma

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5470571A (en) * 1988-01-27 1995-11-28 The Wistar Institute Method of treating human EGF receptor-expressing gliomas using radiolabeled EGF receptor-specific MAB 425
IE63847B1 (en) * 1989-05-05 1995-06-14 Res Dev Foundation A novel antibody delivery system for biological response modifiers
CA2066428C (en) * 1989-09-08 2000-11-28 Bert Vogelstein Structural alterations of the egf receptor gene in human gliomas
US5314995A (en) * 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
ATE218889T1 (de) * 1990-11-09 2002-06-15 Stephen D Gillies Cytokine immunokonjugate
ES2204890T3 (es) * 1991-03-06 2004-05-01 Merck Patent Gmbh Anticuerpos monoclonales humanizados.
JPH06509563A (ja) * 1991-07-05 1994-10-27 セラゲン・インコーポレイテッド 炎症性関節炎の治療用の表皮細胞成長因子受容体を標的とする分子
DE69327620T2 (de) * 1992-08-18 2000-08-03 Immunologia Molecular Ciudad D Monoklonale Antikörper gegen den epidermalen Wachstumsfaktorrezeptor, Zellen und Verfahren zur ihrer Herstellung und sie erhaltende Zusammensetzungen
DK139193D0 (da) 1993-09-24 1993-12-13 Hartmann As Brdr Rektangulaer aegbakke
EP0699237B1 (en) * 1994-03-17 2003-02-19 MERCK PATENT GmbH Anti-egfr single-chain fvs and anti-egfr antibodies

Also Published As

Publication number Publication date
HU9403784D0 (en) 1995-02-28
EP0659439A3 (en) 1996-12-04
KR950016781A (ko) 1995-07-20
NO944980L (no) 1995-06-26
AU688817B2 (en) 1998-03-19
EP0659439B1 (en) 2001-10-24
CZ330694A3 (en) 1995-10-18
HUT70471A (en) 1995-10-30
DE69428764D1 (de) 2001-11-29
RU94045281A (ru) 1996-11-10
JPH07223968A (ja) 1995-08-22
ZA9410282B (en) 1995-08-29
DK0659439T3 (da) 2002-01-14
PL306474A1 (en) 1995-06-26
DE69428764T2 (de) 2002-06-20
AU8159394A (en) 1995-06-29
ATE207366T1 (de) 2001-11-15
CZ289099B6 (cs) 2001-11-14
ES2166368T3 (es) 2002-04-16
SK283494B6 (sk) 2003-08-05
JP2006298936A (ja) 2006-11-02
US6979726B1 (en) 2005-12-27
EP0659439A2 (en) 1995-06-28
UA41888C2 (uk) 2001-10-15
HU219680B (hu) 2001-06-28
NO315903B1 (no) 2003-11-10
CA2138928C (en) 2009-02-17
NO944980D0 (no) 1994-12-22
CA2138928A1 (en) 1995-06-25
RU2129018C1 (ru) 1999-04-20
PL178793B1 (pl) 2000-06-30
SK156294A3 (en) 1995-07-11

Similar Documents

Publication Publication Date Title
DK0659439T3 (da) Immunkonjugater
UA40611C2 (uk) Імунокон'югат, спосіб його виготовлення, фармацевтична композиція
ZA958444B (en) Biological active proteins
DK0961780T3 (da) Proteinmarkörer for lungecancer og anvendelse deraf
TW428026B (en) Bifunctional protein, preparation and use
ATE242322T1 (de) Fusionsprotein , das zwei rezeptoren des tumornekrose-faktors enthält
BR9507594A (pt) Processo para o tratamento de glomerulonefrite em um paciente necessitado deste tratamento artigo de fabricação anticorpo hibridoma 5g.1;1 molécula deácido nucleico proteina isolada polipeptideo isolado vetor de ácido nucleico célula hospedeira recombinante processo para produzir um polipeptideo de anticorpo c5 isolado anticorpo anti-c5 isolado processo para produzir uma proteina de anticorpo anti-c5 isolado molécula de ácido nucleico isolada processo para produzir um anticorpo anti-c5 anticorpo anti-c5 fragmento 5g46k fragmento 5g27k peptideo 5g325aa isolado peptideo 5g200aa isolado oligopeptideo isolado processo para induzir um animal a produzir um anti-c5 processo para identificar um anticorpo anti-c5 e processo para tratar um paciente necessitado de inibiçao complemetar
PT635030E (pt) Conjunto de construcao de brinquedo e um veiculo para o mesmo
NO2007014I2 (no) Anti-VEGF-antistoff, sammensetning, nukleinsyre, vektor, vertcelle, fremgangsmåte samt medikament for medisinsk bruk
AU6046796A (en) Human vascular endothelial growth factor 2
GR1000477B (el) Νεο μονοκλωνικο αντισωμα κατα νεου αντιγονου που σχετιζεται με ανθρωπινους ογκους.
DE69434926D1 (de) Menschlicher gewebsinhibitor von metalloproteinase-4
AU3125289A (en) Monoclonal antibodies directed against human tumor necrosis factor - receptor
MX24652A (es) Compuestos de adn recombinante, vectores para la expresion de formas zimogenas de proteina c humana, celulas huesped transformadas y metodo para la prduccion recombinante de formas zimogenas de la proteina c humana.
ATE241639T1 (de) Keratinozyten-wachstumsfaktor 2
EP1655382A3 (en) Colon specific gene and protein
ATE368687T1 (de) Thrombopoietinproteine mit verbesserten eigenschaften
DK0950062T3 (da) Proteinmarkörer for esophageal cancer
MX24651A (es) Compuestos de adn recombinante, vectores de expresion de mutantes de glicosilacion de la proteina c humana, celulas huesped transformadas y metodo para la produccion recombinante de formas zimogenas de proteina c humana.
ATE223227T1 (de) Verwendung von lbp zur sepsistherapie
MX9706204A (es) Factor 2 de crecimiento de queratinocitos.
MX9709570A (es) Factor de crecimiento 3 endotelial, vascular, humano.